Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fosun Pharma

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA accelerated approval for solid tumours

The ADC has been authorised to treat adults with unresectable or metastatic HER2-positive tumours

Daiichi Sankyo logo

Daiichi Sankyo’s Vanflyta approved by MHRA to treat acute myeloid leukaemia

The blood cancer affects approximately 3,100 people in the UK annually

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu not recommended by NICE for advanced breast cancer

Breast cancer is the most common form of cancer in the UK, accounting for over 55,000 cases every year

- PMLiVE

FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies

The regulator will monitor approved BCMA- or CD19-directed autologous CAR-T cell immunotherapies

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced lung cancer

Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases

- PMLiVE

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Research Partnership

- PMLiVE

Merck and Daiichi Sankyo announce ADC agreement worth up to $22bn

The companies will jointly develop and commercialise three of Daiichi Sankyo’s cancer candidates

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study

More than two million people worldwide are diagnosed with breast cancer every year

- PMLiVE

AstraZeneca and Daiichi Sankyo share positive results from phase 3 lung cancer study

The investigational drug met the dual primary endpoint of progression-free survival

- PMLiVE

Webcast: China Update 2023: How will recent developments impact your brand’s success?

Register for this live webinar in which emerging market experts provide an update regarding the implications of changing demographics and the healthcare landscape.

Research Partnership

- PMLiVE

Janssen signs $245m deal with Cellular Biomedicine for pair of CAR T-cell therapies

The candidates have shown the potential to treat forms of non-Hodgkin’s lymphoma

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer

Breast cancer is one of the leading causes of cancer-related deaths globally, with more than two millions cases diagnosed in 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links